Press Release December 21, 2021ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA 0 0 Share
Company Ticker News December 21, 2021Acadia Slims Nuplazid Label Expansion Application For Alzheimer's Disease Psychosis 0 0 Share
Press Release December 1, 2021The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia 0 0 Share
Company Ticker News November 9, 2021ACADIA Pharmaceuticals (ACAD) CEO Stephen Davis on Q3 2021 Results - Earnings Call Transcript 0 0 Share
Company Ticker News November 8, 2021Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates 0 0 Share
Company Ticker News November 8, 2021Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results 0 0 Share
Press Release November 2, 2021Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021 0 0 Share
Company Ticker News November 1, 2021Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial 0 0 Share
Company Ticker News October 27, 2021Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021 0 0 Share
